

**PCT**WORLD INTELLECTUAL PROPE  
International Bu

WO 9607734A2

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :

C12N 7/01, 15/86

A2

(11) International Publication Number:

WO 96/07734

(43) International Publication Date:

14 March 1996 (14.03.96)

(21) International Application Number: PCT/US95/09904

(22) International Filing Date: 7 August 1995 (07.08.95)

(30) Priority Data:

303,162

8 September 1994 (08.09.94) US

(71) Applicant: GENVEC, INC. [US/US]; 12111 Parklawn Drive, Rockville, MD 20852 (US).


(72) Inventors: WICKHAM, Thomas, J.; 8608 Delcris Drive, Gaithersburg, MD 20879 (US). KOVESDI, Imre; 12505 Village Square Terrace #202, Rockville, MD 20852 (US). BROUGH, Douglas, E.; 3900 Shallowbrook Lane, Olney, MD 20832 (US). McVEY, Duncan, L.; 7727 Ironforge Court, Derwood, MD 20855 (US). BRUDER, Joseph, T.; 6644 Beach Drive, New Market, MD 21774 (US).

(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit &amp; Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

**Published***Without international search report and to be republished upon receipt of that report.*

(54) Title: RECOMBINANT ADENOVIRUS COMPRISING A CHIMERIC PENTON BASE PROTEIN



## (57) Abstract

A recombinant adenovirus comprising a chimeric penton base protein, which includes a nonpenton base sequence, and a therapeutic gene, a method of gene therapy involving the use of such adenovirus, and adenoviral transfer vectors for the generation of such recombinant adenovirus are provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## RECOMBINANT ADENOVIRUS COMPRISING A CHIMERIC PENTON BASE PROTEIN

TECHNICAL FIELD OF THE INVENTION

5       The present invention relates to a recombinant adenovirus comprising a chimeric adenoviral penton base protein and the use of a recombinant adenovirus comprising a chimeric adenoviral penton base protein in gene therapy.

BACKGROUND OF THE INVENTION

10       Adenoviruses belong to the family Adenoviridae, which is divided into two genera, namely Mastadenovirus and Aviadenovirus. Adenoviruses are nonenveloped, regular icosahedrons 65-80 nm in diameter (Horne et al., J. Mol. Biol., 1, 84-86 (1959)). The capsid is composed of 252 capsomeres of which 240 are hexons and 12 are pentons (Ginsberg et al., Virology, 28, 782-783 (1966)). The hexons and pentons are derived from three different viral polypeptides (Maizel et al., Virology, 36, 115-125 (1968); Weber et al., Virology, 76, 709-724 (1977)). The hexon comprises three identical polypeptides of 967 amino acids each, namely polypeptide II (Roberts et al., Science, 232, 1148-1151 (1986)). The penton contains a penton base, which is bound to the capsid, and a fiber, which is noncovalently bound to and projects from the penton base. The fiber protein comprises three identical polypeptides of 582 amino acids each, namely polypeptide IV. The Ad2 penton base protein is an 8 X 9 nm ring-shaped complex composed of five identical protein subunits of 571 amino acids each, namely polypeptide III (Boudin et al., Virology, 92, 125-138 (1979)). Proteins IX, VI, and IIIa are also present in the adenovirus coat and are thought to stabilize the viral capsid (Stewart et al., Cell, 67, 145-154 (1991); Stewart et al., EMBO J., 12(7), 2589-2599 (1993)).

35       Once an adenovirus attaches to a cell, it undergoes receptor-mediated internalization into clathrin-coated

endocytic vesicles of the cell (Svensson et al., J. Virol., 51, 687-694 (1984); Chardonnet et al., Virology, 40, 462-477 (1970)). Virions entering the cell undergo a stepwise disassembly in which many of the viral  
5 structural proteins are shed (Greber et al., Cell, 75, 477-486 (1993)). During the uncoating process, the viral particles cause disruption of the cell endosome by a pH-dependent mechanism (Fitzgerald et al., Cell, 32, 607-617 (1983)), which is still poorly understood. The viral  
10 particles are then transported to the nuclear pore complex of the cell (Dales et al., Virology, 56, 465-483 (1973)), where the viral genome enters the nucleus, thus initiating infection.

An adenovirus uses two separate cellular receptors,  
15 both of which must be present, to attach to and efficiently infect a cell (Wickham et al., Cell, 73, 309-319 (1993)). First, the fiber protein attaches the virus to a cell by binding to an, as yet, unidentified receptor. Then, the penton base binds to  $\alpha_v$  integrins.  
20 Integrins are a family of heterodimeric cell surface receptors that mediate cellular adhesion to the extracellular matrix molecules fibronectin, vitronectin, laminin, and collagen, as well as other molecules (Hynes, Cell, 69, 11-25 (1992)). Integrins are known to play  
25 important roles in cell signaling processes, including calcium mobilization, protein phosphorylation, and cytoskeletal interactions (Hynes, supra). The specificity with which an integrin binds to a particular ligand, such as those associated with an adenovirus, is a  
30 function of the paired  $\alpha$  and  $\beta$  subunits of the integrin. For example, integrin  $\alpha_6\beta_1$  binds to laminin, integrin  $\alpha_2\beta_1$  binds to collagen and laminin, and integrin  $\alpha_3\beta_1$  binds to collagen, laminin, and fibronectin. Furthermore, different tissue types may have different complements of  
35 integrin subunits, thereby providing a mode of spatial control over integrin-ligand signal transfer or over ligand internalization. Accordingly, some integrins,

such as those that include subunit  $\alpha_v$ , are broadly expressed on numerous cell types, whereas other integrins have a much more narrow tissue distribution. For example, the integrins that include subunit  $\beta_2$  are  
5 expressed only on leukocytes, such as neutrophils and macrophages, integrins including subunit  $\alpha_4$  are expressed only on lymphocytes and fibroblasts, and the integrin defined by the subunits  $\alpha_{IIb}\beta_3$  is expressed only on  
platelets and megakaryocytes.

10 The specificity of integrin subunit complement also extends to the infectability of cells by different serotypes of adenovirus, because the particular  $\alpha$  and  $\beta$  subunits dictate whether a virus can enter a cell. For example, the penton base of the adenovirus serotype Ad2  
15 binds to integrins  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  (Wickham et al. (1993), supra). Given that both receptors utilized by an adenovirus are expressed on most human cells, nearly all cells in a human body are susceptible to adenoviral infection.

20 A majority of integrins have been found to recognize short linear stretches of amino acids in binding to a specific ligand. The tripeptide motif arg-gly-asp (RGD), which is found in scores of matrix ligands, including laminin, fibronectin, collagen, vitronectin, and  
25 fibrinogen, has been implicated in the binding of  $\alpha_3\beta_1$ ,  $\alpha_5\beta_1$ ,  $\alpha_{IIb}\beta_3$ ,  $\alpha_m\beta_2$ , and most, if not all, of the five  $\alpha_v$ -containing integrins. The conformation of the RGD sequence within a matrix ligand is thought to be a primary factor in integrin specificity (Pierschbacher et al., J. Biol. Chem., 262, 17294-17298 (1987)). Sequences  
30 that directly flank the RGD sequence have been shown to influence integrin specificity, presumably because of their effect on RGD conformation (Smith et al., Proc. Natl. Acad. Sci. USA, 90, 10003-10007 (1993)). However,  
35 sequences distant from the RGD may also function in integrin specificity as has been shown for the binding of  $\alpha_5\beta_1$  to fibronectin (Obara et al., Cell, 53, 649-657

(1988)). Other integrins, which do not utilize RGD, have been found to bind similar short linear stretches of amino acids within their specific ligands. For example, integrin  $\alpha_{\text{IIb}}\beta_3$  binds via the amino acid sequence lys-gln-ala-gly-asp (KQAGD) [SEQ ID NO:1] in fibrinogen (Kloczewiak et al., Biochemistry, 23, 1767-1774 (1984)), while  $\alpha_4\beta_1$  binds via the core sequence glu-ile-leu-asp-val (EILDV) [SEQ ID NO:2] in fibronectin (Komoriya et al., J. Biol. Chem., 266, 15075-15079 (1991)). A structural motif (i.e., asn-pro-xaa-try (NPXY)) present in the  $\beta$  subunits of  $\alpha_v$ -containing integrins has been shown to be important for internalization (Suzuki et al., Proc. Natl. Acad. Sci. USA, 87, 5354 (1990)).

The penton base sequence is highly conserved among serotypes of adenovirus and contains five copies of the RGD tripeptide motif (Neumann et al., Gene, 69, 153-157 (1988)). The RGD tripeptide is believed to mediate binding to  $\alpha_v$  integrins because exogenously added RGD peptides can block penton base binding and adenoviral infection (Wickham et al. (1993), supra), and adenoviruses that have point mutations in the RGD sequence of the penton base are restricted in their ability to infect cells (Bai et al., J. Virol., 67, 5198-5205 (1993)).

The penton base genes from Ad2, Ad5, Ad12, and Ad40 serotypes of adenovirus have been sequenced. Alignment of the sequences reveals a high degree of conservation over the entire sequence, except for the N-terminus, and, in Ad2, Ad5, and Ad12, a hypervariable region that includes the RGD sequence. Only Ad40, one of two enteric adenoviral serotypes, does not have an RGD sequence. Ad2 and Ad5 are identical in the hypervariable region and contain a large insert of amino acids flanking either side of the RGD sequence. Secondary structural analysis of the hypervariable regions of the three RGD-containing penton bases predicts that, in each case, the RGD is flanked by  $\alpha$ -helices. Such structures are believed to

form the spikes seen in cryo-electron micrographic (cryo-EM) images of Ad2 penton bases (Stewart et al. (1993), supra).

Recombinant adenoviral vectors have been used for  
5 the cell-targeted transfer of one or more recombinant  
genes to diseased cells or tissue in need of treatment.  
Such vectors are characterized by the further advantage  
of not requiring host cell proliferation for expression  
of adenoviral proteins (Horwitz et al., In Virology,  
10 Raven Press, New York, vol. 2, pp. 1679-1721 (1990); and  
Berkner, BioTechniques, 6, 616 (1988)), and, if the  
targeted tissue for somatic gene therapy is the lung,  
these vectors have the added advantage of being normally  
trophic for the respiratory epithelium (Straus, In  
15 Adenoviruses, Plenan Press, New York, pp. 451-496  
(1984)).

Other advantages of adenoviruses as potential  
vectors for human gene therapy are as follows:

(i) recombination is rare; (ii) there are no known  
20 associations of human malignancies with adenoviral  
infections despite common human infection with  
adenoviruses; (iii) the adenoviral genome (which is a  
linear, double-stranded DNA) can be manipulated to  
accommodate foreign genes that range in size; (iv) an  
25 adenoviral vector does not insert its DNA into the  
chromosome of a cell, so its effect is impermanent and  
unlikely to interfere with the cell's normal function;  
(v) the adenovirus can infect non-dividing or terminally  
differentiated cells, such as cells in the brain and  
30 lungs; and (vi) live adenovirus, having as an essential  
characteristic the ability to replicate, has been safely  
used as a human vaccine (Horwitz et al. (1990), supra;  
Berkner et al. (1988), supra; Straus et al. (1984),  
supra; Chanock et al., JAMA, 195, 151 (1966); Haj-Ahmad  
35 et al., J. Virol., 57, 267 (1986); and Ballay et al.,  
EMBO, 4, 3861 (1985)).

The problem of using a recombinant adenovirus in gene therapy is that all cells that express the aforementioned two receptors used by the adenovirus to attach and infect a cell will internalize the gene(s) being administered — not just the cells in need of therapeutic treatment. Likewise, certain cells, such as lymphocytes, which lack the  $\alpha_v$  integrin adenoviral receptors, will be severely impaired in the uptake of an adenovirus and will not be easily amenable to adenovirus-mediated gene delivery. Accordingly, limiting adenoviral entry to specific cells and/or expanding the repertoire of cells amenable to adenovirus-mediated gene therapy would be a significant improvement over the current technology. Targeted adenoviral gene delivery should expand the cells amenable to gene therapy, reduce the amount of adenoviral vector that is necessary to obtain gene expression in the targeted cells, as well as reduce side effects and complications associated with increasing doses of an adenovirus, such as inflammation and the transfection of normal, healthy cells.

Attempts have been made to target a virus to specific cells by sterically blocking adenoviral fiber protein with antibodies and chemically linking tissue-specific antibodies to the viral particle (Cotten et al., Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992)). Although this approach has demonstrated the potential of targeted gene delivery, the complexity and reproducibility of this approach present major hurdles blocking its application in clinical trials. The difficulties thus far encountered in targeting the virus by these methods involve the method of synthesis required, which is to make major alterations in the viral particles following their purification. These alterations involve additional steps that covalently link large molecules, such as polylysine, receptor ligands and antibodies, to the virus. The targeted particle complexes are not homogeneous in structure and their



efficiency is sensitive to the relative ratios of viral particles, linking molecules, and targeting molecules used.

The present invention seeks to overcome the problem of lack of cell and tissue specificity of recombinant adenoviral gene therapy. It is an object of the present invention to provide a receptor-specific, preferably cell receptor-specific/tissue receptor-specific, recombinant adenovirus. A further object of the present invention is to provide means for generating such a recombinant adenovirus at the level of gene expression, thereby enabling purification of recombinant adenoviral particles by conventional techniques. Another object of the present invention is to provide a method of gene therapy involving the use of such a homogeneous adenovirus, without the need for additional components or further modification. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the following detailed description.

#### BRIEF SUMMARY OF THE INVENTION

The present invention provides a recombinant adenovirus comprising a chimeric penton base protein that selectively binds to a given receptor, preferably a cell-specific/tissue-specific receptor, an adenoviral transfer vector comprising a recombinant penton base gene for the generation of a chimeric penton base protein, and a method of using a receptor-specific recombinant adenovirus comprising a therapeutic gene in gene therapy.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a partial restriction map of an adenoviral transfer vector (pAT).

Figure 2 is a partial restriction map of the vector pRcPB5 ( $\Delta$ RGD).

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides, among other things, a recombinant adenovirus comprising a chimeric penton base protein. The chimeric penton base protein comprises  
5 a nonpenton base amino acid sequence, which is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in addition to or in place of a wild-type penton base amino acid sequence, preferably an amino acid sequence that is specific for binding to a receptor,  
10 most preferably an RGD amino acid sequence.

By "nonpenton base amino acid sequence" is meant any amino acid sequence that is not found in a wild-type penton base. Preferably, the nonpenton base sequence is less than ten amino acids, more preferably less than five  
15 amino acids, and most preferably about three amino acids. By "RGD amino acid sequence" is meant the RGD amino acid sequence and the RGD amino acid sequence along with up to or including three amino acids flanking either or both sides of the RGD amino acid sequence. The nonpenton base  
20 amino acid sequence renders the adenovirus specific for a given receptor, preferably a cell-specific or tissue-specific receptor, or specific for a given receptor-specific antibody domain or epitope. The receptor is preferably one that the wild-type adenovirus does not  
25 bind or one that the wild-type adenovirus binds but with greater specificity upon the introduction of the nonpenton base amino acid sequence into the chimeric penton base protein.

Preferably, the RGD amino acid sequence of the  
30 penton base protein has been replaced at the DNA level with an amino acid binding sequence for a given receptor, receptor-specific antibody domain or epitope. Alternatively, the RGD amino acid sequence has been rendered inactive at the DNA level by mutation of the RGD  
35 amino acid sequence, such as by insertional mutagenesis, for example, or rendered conformationally inaccessible in the penton base protein, such as by insertion of a DNA

sequence into or adjacent to the adenoviral penton base gene sequence, wherein "gene sequence" refers to the complete penton base gene sequence as well as any lesser gene sequences that are capable of being expressed as functional penton base protein. Preferably, the DNA sequence is inserted near the gene sequence encoding the RGD amino acid sequence, so as to move the gene sequence encoding the RGD amino acid sequence within the penton base gene sequence such that in the chimeric penton base protein the RGD amino acid sequence is conformationally inaccessible for binding to a receptor. In the latter case, the inserted nonpenton base gene sequence that causes the conformational inaccessibility of the RGD amino acid sequence in the penton base protein is preferably one that encodes an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope. Such a recombinant adenovirus can be used, for example, to study receptor binding, adenoviral attachment, and adenoviral infection in vitro or in vivo.

In a preferred embodiment of the present invention, the above-described recombinant adenovirus additionally comprises a gene capable of being expressed in a cell to which the virus has attached or by which the virus has been internalized and preferably is one having therapeutic utility. In yet another preferred embodiment of the present invention, the recombinant adenovirus is fiberless or further comprises a chimeric coat protein, such as a fiber or hexon, that includes an amino acid sequence that is specific for a receptor, a receptor-specific antibody domain or epitope, preferably one that is specific for the same receptor, antibody domain or epitope as the nonpenton base sequence. Such recombinant adenovirus can be used, for example, to study the effects of expression of the gene in a given cell or tissue in vitro or in vivo. Alternatively, the recombinant adenovirus can be used for gene therapy.

The recombinant adenovirus comprising a chimeric penton base protein and the recombinant adenovirus that additionally comprises a gene capable of being expressed in a particular cell can be generated by use of a viral transfer vector, preferably an adenoviral transfer (pAT) vector, in accordance with the present invention. The viral transfer vector, preferably the pAT vector, comprises a chimeric adenoviral penton base gene sequence. The chimeric penton base gene sequence comprises a nonpenton base sequence in place of the RGD amino acid sequence, which has been deleted, or in addition to the RGD amino acid sequence, which has been mutated or rendered conformationally inaccessible in the expressed chimeric penton base protein as described above. The nonpenton base sequence renders the adenovirus specific for binding to a receptor, receptor-specific antibody domain or epitope also as described above. Given that the penton base gene has been shown to be >90% conserved among 5 of the approximately 41 serotypes of adenovirus, it is expected that any one of the serotypes of adenovirus may be used as the source of the penton base gene. It is preferred, however, that one of the serotypes for which the penton base gene has been sequenced is used.

Restriction sites that are unique with respect to the adenoviral genome are introduced into the penton base gene sequence; preferably, such restriction sites are introduced into or flanking the RGD region of the penton base gene sequence by a suitable method, such as PCR mutagenesis. These unique restriction sites may be any restriction site not already present in the penton base gene, and are preferably Eco RI and/or Spe I. Such sites facilitate the removal, inactivation, such as by sequence alteration, of the DNA sequence encoding the RGD amino acid sequence in a given adenoviral genome, such as a wild-type adenovirus, or the rendering of the RGD amino acid sequence conformationally inaccessible, thereby

altering or eliminating the ability of the penton base molecule to bind an  $\alpha_v$  integrin receptor. A deleted RGD amino acid sequence can be replaced with, or a mutated or conformationally inaccessible RGD sequence can be  
5 accompanied by, a different DNA sequence, preferably a DNA sequence encoding specificity for binding to a receptor, preferably a cell-specific or tissue-specific cell-surface receptor, or to a receptor-specific antibody domain or epitope, for example.

10 Preferably, the pAT vector is one into which any suitable receptor-specific sequence can be rapidly inserted. For example, a unique Spe I restriction site can be used to remove the RGD amino acid sequence. Alternatively, sequences also can be inserted into the  
15 penton base gene sequence without the need for unique restriction sites through PCR. Because a recombinant adenovirus can be created via ligation of recombinant sequences with viral DNA or via homologous recombination, the pAT vector preferably has either (1) unique  
20 restriction sites that allow ligation of a vector fragment with the complementing fragments of the remaining viral genomes, as described in Example 4, or (2) adequate lengths of DNA on either side of the receptor-specific or antibody domain- or epitope-specific  
25 sequence that allow efficient homologous recombination with viral DNA, as described in Example 5. A preferred pAT vector is shown in Figure 1, which is a partial restriction map of such a vector. The pAT of Figure 1 was generated as described in Example 1.

30 DNA encoding short peptide sequences or protein domains capable of binding to a given receptor, preferably a specific cell or tissue receptor, and capable of being internalized by the receptor, such as the receptor that is resident on leukocytes, is preferred  
35 for insertion into the penton base gene sequence in which the RGD amino acid sequence has been deleted, mutated, or rendered conformationally inaccessible. However, other

DNA sequences, such as those that encode receptor-specific antibody domains and sequences that encode antigenic epitopes recognized by specific antibodies also may be used to replace the RGD amino acid sequence.

5       The size of the DNA used to replace the RGD amino acid sequence may be constrained, for example, by impeded folding of the penton base and improper assembly of the penton base/fiber complex. However, cryo-EM analysis of the penton base indicates that, if the RGD amino acid  
10       sequence exists at the spikes of the penton bases, there may be considerable room to accommodate large inserts without folding or assembly being affected adversely. Also, the large differences in size between the hypervariable region of the Ad5 penton base and the Ad12  
15       penton base indicates that the hypervariable region may be able to accommodate inserts of various sizes. Of course, assembly of the penton complex probably will not be an issue with respect to viruses that are constructed without a fiber molecule.

20       The target receptor can be any receptor that is internalized by a cell, is optimally cell-specific or tissue-specific, and desirably is expressed only on those cells or tissue to be treated. Tissue-specific integrins are preferred target receptors for chimeric penton base  
25       molecules for four reasons. First, many integrins bind ligands via short linear stretches of amino acids, and these stretches have been identified for many integrins. Second, certain integrins are tissue-specific for cells amenable to targeted gene therapy. For example,  $\beta_2$ -  
30       containing integrins are expressed only in leukocytes, thus allowing targeted delivery to normally non-susceptible target cells while also preventing delivery to normally susceptible non-target cells. Third, the wild-type penton base uses  $\alpha_v$  integrins to enter cells so  
35       that the use of a related integrin molecule is more apt to be successful than the use of an unrelated receptor. Fourth, integrins are efficiently internalized into the

cell (Bretscher, EMBO, 11, 405-410 (1992)), which is required for viral infection of cells.

Changing the penton base protein such that it recognizes a receptor, such as a cell-specific or tissue-specific cell-surface receptor, typically will not alter viral particle attachment to cells because cell attachment is mediated by the adenoviral fiber protein. Infection of the cells to which the chimeric penton base protein has attached, however, will be generally impeded because the virus requires the presence of an  $\alpha_v$  integrin to enter the cell. Therefore, an adenovirus with altered penton bases will bind to most cells but will enter only those cells expressing the receptor (e.g., the integrin) for the chimeric penton base. Those cells unable to express the appropriate receptor nonetheless will have adenoviral particles tethered on the cell membrane because the viral particles will be unable to enter the cell. Consequently, tethered adenoviral particles will be exposed to the immune system and disposed of accordingly.

Following fiber-mediated viral attachment to cells, it is possible that some virus may manage to non-specifically enter cells not expressing the cell- or tissue-specific receptor recognized by the chimeric penton base. Therefore, some leakiness in cell-specific or tissue-specific expression may be observed. However, if this is the case, fiber-deficient viral particles can be constructed that use the penton base as the primary cell attachment protein. It is known that fiber protein is nonessential for virion assembly or infectivity of cells (Falgout et al., J. Virology, 62, 622-625 (1988)). Such mutant adenoviral particles lacking fiber protein adsorb onto cells at a ten-fold lower rate. The fact that the mutant viruses do adsorb and at a lower rate than wild-type particles indicates that the adsorption is mediated by the penton base/ $\alpha_v$  integrin interaction, which has a 30-fold lower affinity than the fiber/fiber-

receptor interaction (Wickham et al. (1993), supra). Accordingly, both attachment and internalization can be restricted only to those cells expressing the desired tissue-specific receptor.

5           By replacing the low affinity RGD amino acid sequence in a wild-type penton base with an amino acid sequence with a high affinity for a given receptor, such as a cell-specific or tissue-specific receptor, it is possible to generate a fiberless viral particle with as  
10           high, or higher, affinity for targeted cells than the wild-type fiber-expressing virus. Fiberless viral particles containing a chimeric penton base, compared to fiber-containing viral particles, can be targeted more effectively to tissues because the altered virus is able  
15           to bind only to the cells expressing the cell-specific or tissue-specific receptor recognized by the chimeric penton base. The desired ligand and receptor characteristics are as described above.

          A recombinant chimeric penton base gene sequence can  
20           be moved from a pAT vector into baculovirus or a suitable prokaryotic or eukaryotic expression vector for expression and evaluation of receptor specificity, avidity, and other biochemical characteristics. Accordingly, the present invention also provides  
25           recombinant baculoviral and prokaryotic and eukaryotic expression vectors comprising a chimeric adenoviral penton base gene sequence. The chimeric penton base gene sequence includes a nonpenton base sequence in addition to or in place of a wild-type penton base amino acid  
30           sequence, such as an RGD amino acid sequence, which is specific for binding to a receptor. The wild-type penton base amino acid sequence may be deleted, mutated, or rendered conformationally inaccessible as described above with respect to the recombinant adenovirus comprising a  
35           chimeric penton base protein. By moving the chimeric gene from pAT to baculovirus or a prokaryotic or eukaryotic expression vector, high protein expression is



achievable, resulting in approximately 50% of the total protein of the host being the chimeric penton base. Accordingly, the present invention also provides a recombinant baculovirus comprising a chimeric penton base protein and a chimeric adenoviral penton base protein comprising a nonpenton base amino acid sequence in addition to or in place of a wild-type penton base amino acid sequence, such as an RGD amino acid sequence, which is specific for binding to a receptor. The nonpenton base amino acid sequence is specific for binding to a receptor or a receptor-specific antibody domain or epitope as described above. For protein characterization studies, the recombinant chimeric penton base protein (rcPB protein, such as rcPB5) can be purified using any suitable methods, such as those described by Wickham et al. (1993), supra.

Various characteristic parameters of the penton base protein of interest can be assessed as follows: Adhesion assays are used to evaluate the specificity of the interaction of the rcPB protein with its designated receptor, using the method of Wickham et al. (1993), supra, for example. Specificity and affinity of the receptor/rcPB interaction is assessed by Scatchard analysis as shown previously by Wickham et al. (1993), supra, for wild-type penton base protein. Receptor specificity is further assessed by using antibodies and peptides specific for the targeted receptor to block rcPB5 binding to cells, using conventional methods. Internalization is assayed with rcPB protein and recombinant adenoviruses, e.g., Ad5 rcPB, as described previously by Wickham et al. (1993), supra, for example. rcPB binding to fiber protein is assessed by its ability to precipitate radiolabeled fiber molecules when coupled to protein A-coated beads via an antibody to the penton base molecule. Alternatively, fiber binding can be assessed in an ELISA-based assay in which rcPB is coated onto ELISA plates followed by incubation of immobilized

rcPB with soluble fiber molecules, using conventional methods. Fiber binding to the rcPB protein is then assessed by a further incubation with antibody specific for the fiber molecule, via conventional techniques.

5       Virus entry and gene expression are evaluated initially by using the pAT vector containing the insert of interest to generate recombinant virus expressing the chimeric penton base protein and a marker gene, such as  $\beta$ -glucuronidase.  $\beta$ -glucuronidase expression in cells  
10       infected with adenovirus containing the  $\beta$ -glucuronidase gene (Ad-Gluc) can be detected as early as two hours after adding Ad-Gluc to cells. This procedure provides a quick and efficient analysis of cell entry of the recombinant virus and gene expression, and is implemented  
15       readily by an artisan of ordinary skill using conventional techniques.

      A recombinant virus, which lacks a wild-type receptor binding sequence, such as the RGD amino acid sequence, in the penton base protein, can be produced in  
20       human embryonic cell line 293 (HEK 293), which has been shown to be able to replicate recombinant adenoviral particles lacking the RGD sequence, using previously described techniques (Bai et al. (1993), supra). A recombinant virus, which lacks functional fiber proteins  
25       and in which the penton base acts as both the viral attachment and internalization protein, may be produced in cell lines which express the receptor to which the rcPB5 protein is targeted. For example, Ad5 rcPB5 containing an insert specific for  $\alpha_v\beta_3$  can be produced in  
30       HeLa cells that express  $\alpha_v\beta_3$  or 293 cells transfected with the gene for  $\alpha_v\beta_3$ .

      The chimeric penton base protein may be present in the viral particle with the fiber, without the fiber (in which case the rcPB protein functions as the virus  
35       attachment and internalization protein), with a recombinant fiber molecule that is specific for a receptor, such as a cell-specific or tissue-specific

receptor, or with a recombinant coat protein that is specific for a receptor, such as a cell-specific or tissue-specific receptor. See Examples 4-9 for a further description of these embodiments of the invention.

5       Recombinant adenoviruses of the present invention can be used to treat any one of a number of diseases by delivering to targeted cells corrective DNA, i.e., DNA encoding a function that is either absent or impaired, or a discrete killing agent, e.g., DNA encoding a cytotoxin  
10       that, for example, is active only intracellularly, or DNA encoding ribozymes or antisense molecules, for example. Accordingly, use of the term "therapeutic gene" is intended to encompass these and other embodiments of that which is more commonly referred to as gene therapy and is  
15       known to those of skill in the art. Diseases that are candidates for such treatment include, for example, cancer, e.g., melanoma or glioma, cystic fibrosis, genetic disorders, and pathogenic infections, including HIV infection. For example, a recombinant adenovirus  
20       having a penton base molecule recognized by  $\alpha_v\beta_3$  receptors can be used to treat melanoma or glioma, and a recombinant adenovirus recognized by  $\alpha_3\beta_1$  receptors and expressing the cystic fibrosis transmembrane regulator (CFTR) gene can be used to treat cystic fibrosis by  
25       delivery to the epithelial cells of the lungs. Furthermore, various blood-related diseases can be treated by using a recombinant adenovirus recognized by  $\alpha_m\beta_2$  receptors to target neutrophils and macrophages, a recombinant adenovirus recognized by  $\alpha_4\beta_1$  receptors to  
30       target lymphocytes, a recombinant adenovirus recognized by  $\alpha_{IIb}\beta_3$  receptors to target platelets and megakaryocytes, and a recombinant adenovirus recognized by  $\alpha_v\beta_3$  integrins to target endothelial cells undergoing angiogenesis.

35       One skilled in the art will appreciate that suitable methods of administering a recombinant adenovirus of the present invention to an animal for purposes of gene

therapy (see, for example, Rosenfeld et al., Science,  
252, 431-434 (1991); Jaffe et al., Clin. Res., 39(2),  
302A (1991); Rosenfeld et al., Clin. Res., 39(2), 311A  
(1991); Berkner, BioTechniques, 6, 616-629 (1988)),  
5 chemotherapy, and vaccination are available, and,  
although more than one route can be used to administer  
such a recombinant adenovirus, a particular route can  
provide a more immediate and more effective reaction than  
another route. Pharmaceutically acceptable excipients  
10 are also well-known to those who are skilled in the art,  
and are readily available. The choice of excipient will  
be determined in part by the particular method used to  
administer the recombinant adenovirus. Accordingly,  
there is a wide variety of suitable formulations for use  
15 in the context of the present invention. The following  
methods and excipients are merely exemplary and are in no  
way limiting.

Formulations suitable for oral administration can  
consist of (a) liquid solutions, such as an effective  
20 amount of the compound dissolved in diluents, such as  
water, saline, or orange juice; (b) capsules, sachets or  
tablets, each containing a predetermined amount of the  
active ingredient, as solids or granules; (c) suspensions  
in an appropriate liquid; and (d) suitable emulsions.  
25 Tablet forms can include one or more of lactose,  
mannitol, corn starch, potato starch, microcrystalline  
cellulose, acacia, gelatin, colloidal silicon dioxide,  
croscarmellose sodium, talc, magnesium stearate, stearic  
acid, and other excipients, colorants, diluents,  
30 buffering agents, moistening agents, preservatives,  
flavoring agents, and pharmacologically compatible  
excipients. Lozenge forms can comprise the active  
ingredient in a flavor, usually sucrose and acacia or  
tragacanth, as well as pastilles comprising the active  
35 ingredient in an inert base, such as gelatin and  
glycerin, or sucrose and acacia, emulsions, gels, and the

like containing, in addition to the active ingredient, such excipients as are known in the art.

The recombinant adenovirus of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.

Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

Additionally, the recombinant adenovirus of the present invention may be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.

with the gene of interest, the composition employed, the method of administration, and the particular site and organism being treated. However, the dose should be sufficient to effect a therapeutic response.

5 In addition to the recombinant adenovirus of the present invention, the adenoviral transfer vector also has utility in vitro. It can be used as a research tool in the study of adenoviral attachment and infection of cells and in a method of assaying receptor-ligand  
10 interaction. Similarly, the recombinant penton base protein comprising a nonpenton base amino acid sequence in addition to or in place of a wild-type receptor binding sequence, preferably the RGD sequence, can be used in receptor-ligand assays and as adhesion proteins  
15 in vitro or in vivo, for example.

The following examples further illustrate the present invention and, of course, should not be construed as in any way limiting its scope.

#### 20 Example 1

This example describes the construction of the adenoviral transfer vector (pAT) for making chimeric penton base molecules.

pAT, a partial restriction map of which is shown in  
25 Figure 1, was created by cloning the unique Bam HI/Pme I fragment (13259-21561) from the Ad5 genome into pNEB 193 R1-, a minor derivative of pNEB 193 (New England Biolabs, Beverly, MA), from which the unique Eco RI restriction site was removed (SEQ ID NO:5). The resulting vector was  
30 called pNEB 193 R1- [Ad5 (Bam HI/Pme I)].

Two pairs of PCR primers were synthesized and used to amplify a region upstream (left side) and a region downstream (right side) from the RGD sequence. A unique Spe I site was inserted into the antisense primer  
35 (A5a(15147)S, SEQ ID NO:14) used to amplify the upstream region between the RGD sequence and a Bst XI site (15017). The Bst XI site is 35 bp upstream from the

penton base start codon (15052). A unique Spe I site was also inserted into the sense primer (A5a(15204)S, SEQ ID NO:13) to amplify the right side of the gene between the ~~RGD~~ amino acid sequence and an Asc I site (15671). The antisense primer (A5a(15659)) used to amplify the right side of the gene is shown as SEQ ID NO:12. The sense primer (A5s(14153)E; SEQ ID NO:11) for the left side of the gene includes the naturally occurring Bst XI site (15017) and also contains a unique Eco RI site 13 bp upstream from the penton base start codon, which is not in the original sequence. Using these primers, the left and right sides of the penton base gene were amplified and then cloned into pNEB 193 R1' [Ad5 (Bam HI/Pme I)] to create the pAT vector.

The net results of this cloning were the generation of a unique Eco RI site just upstream of the penton base start codon (SEQ ID NO:3) to facilitate subcloning into a baculovirus transfer vector and to facilitate the generation of a recombinant adenovirus using the pAT vector; the deletion of an 8 amino acid region (SEQ ID NO:9) within the wild-type penton base containing the  $\alpha_v$  integrin binding domain; and the incorporation of a unique Spe I site encoding the amino acids threonine and serine in place of the deleted region (SEQ ID NO:7) so that alternative DNA sequences encoding receptor-binding amino acid motifs or other sequences of amino acids can be inserted at that site.

#### Example 2

This example describes the construction of the base vector pRcPB5 ( $\Delta$ RGD) for all cloning used to make a recombinant baculovirus for the expression of a recombinant chimeric Ad5 penton base protein (rcPB5 protein) and for making rcPB5 genes for incorporation into pAT and other related vectors.

pRcPB5 ( $\Delta$ RGD), a partial restriction map of which is shown in Figure 2, was created by cloning the Eco RI/Bgl

II fragment from pAT into the baculovirus transfer vector pAcSG2 (Pharmingen, San Diego, CA). A new sequence encoding a receptor binding domain is inserted into the unique Spe I site within the penton base gene in pRcPB5 (ΔRGD). The resulting vector is then used to generate recombinant baculovirus constructs so that rcPB5 protein can be generated in large quantities and evaluated. Based on evaluation of the recombinant protein, the Eco RI/Bgl II fragment from the pRcPB5 derivative is then cloned into pAT to make the recombinant adenovirus (Ad5 rcPB).

### Example 3

This example describes the cloning of integrin sequences into the Spe I site of the pRcPB5 (ΔRGD) vector of Example 2.

A sequence recognized by a specific integrin receptor is cloned into the penton base cassette as follows. Overlapping sense and antisense oligonucleotides encoding a desired integrin-specific sequence are synthesized. For example, the overlapping sense (Beta 3RGDs, SEQ ID NO:17) and antisense (Beta 3RGDa, SEQ ID NO:18) oligonucleotides that encode sequences that are specific for the integrin  $\alpha_v\beta_3$  (SEQ ID NO:15) and the overlapping sense (CS-1s, SEQ ID NO:21) and antisense (CS-1a, SEQ ID NO:22) oligonucleotides that encode sequences that are specific for the integrin  $\alpha_4\beta_1$  are synthesized. The sense and antisense sequences for each are mixed and converted to full-length double-stranded sequences by filling in the unpaired nucleotides with Klenow fragment. The resulting double-stranded sequence is then inserted into the Spe I site of the pRcPB5 (ΔRGD) vector following digestion with the endonucleotides Xba I and Spe I. The resulting vectors, pRcPB5( $\alpha_v\beta_3$ ) and pRcPB5( $\alpha_4\beta_1$ ), are used to create the recombinant baculovirus vectors, AcNPV rcPB5( $\alpha_v\beta_3$ ) and AcNPV rcPB5( $\alpha_4\beta_1$ ). The rcPB5 protein produced in insect



recombinant baculovirus vectors, AcNPV rcPB5( $\alpha_v\beta_3$ ) and AcNPV rcPB5( $\alpha_4\beta_1$ ). The rcPB5 protein produced in insect cells using the aforementioned baculovirus vectors is evaluated as described above. Based on the analyses in the baculovirus expression system, the Eco RI/Bgl II fragment from each of the vectors then is cloned into a pAT vector to produce the adenoviral vectors, pAT rcPB5( $\alpha_v\beta_3$ ) and pAT rcPB5( $\alpha_4\beta_1$ ).

#### 10 Example 4

This example illustrates the creation of recombinant adenovirus particles containing a wild-type fiber protein and a chimeric penton base specific for  $\alpha_4$  integrins (Ad5 rcPB5 ( $\alpha_4$ ):wtFiber).

15 A chimeric penton base specific for  $\alpha_4$  integrin (Ad5 rcPB5 ( $\alpha_4$ ):wtFiber) can be constructed through ligation of plasmid DNA with viral DNA, which chimeric construct then can be transfected into cells using standard methods. The pAT vector containing the desired chimeric form of penton base is digested with Xmn I to generate a 1 kb piece of DNA containing the receptor-specific coding sequence. Ad5 DNA is digested with the restriction endonuclease Xmn I, which cuts wild-type Ad5 at positions 14561 and 15710 within the Ad5 genome. The two larger 25 fragments are purified away from the smaller 1 kb piece containing the sequence encoding RGD and then ligated with the Xmn I fragment from the pAT vector. The ligated fragments are then transfected into the appropriate cell line to produce recombinant virus. The virus produced 30 from the cells can be plaque purified and verified to contain the chimeric penton base gene using PCR. The penton base produced in the Ad5-infected cells can be also purified, and its receptor-specificity verified.

#### 35 Example 5

This example illustrates the creation of recombinant adenovirus particles containing wild-type fiber protein

and chimeric penton base specific for  $\alpha_4$  integrins (Ad5 rcPB5 ( $\alpha_4$ ):wtFiber).

Adenovirus particles having a chimeric penton base specific for  $\alpha_4$  integrins (Ad5 rcPB5 ( $\alpha_4$ ):wtFiber) can be constructed through transfection of plasmid DNA and viral DNA into cells and generation of recombinants through homologous recombination. The pAT vector containing the desired chimeric form of penton base is linearized by digestion with Bam HI. Ad5 DNA is digested with the restriction endonuclease Xmn I which cuts wild type Ad5 at positions 14561 and 15710 within the Ad5 genome. These two unique sites within the Ad5 genome flank the Spe I site in the pAT vector. The linearized pAT vector and the Xmn I-digested Ad5 DNA are then transfected into the appropriate cell line, such as 293 cells, to produce a recombinant virus by homologous recombination. The virus produced from such cells can be plaque purified and verified to contain the chimeric penton base gene using PCR. The penton base produced in Ad5-infected cells also can be purified, and its receptor-specificity verified.

#### Example 6

This example illustrates the creation of recombinant adenovirus particles lacking fiber protein and chimeric penton base specific for  $\alpha_4$  integrins (Ad5 rcPB5 ( $\alpha_4$ ):-Fiber).

The Ad5 rcPB5 ( $\alpha_4$ ):wtFiber viral DNA can be digested with Bam HI and the 0-59 map unit (m.u.) fragment purified. The fiber gene can be deleted from plasmid containing the Ad5 Bam HI/Sal I fragment (genome map units 59-100). The resultant plasmid is then digested with Bam HI and Sal I, ligated to the 0-59 m.u. piece of Ad5 rcPB5 ( $\alpha_4$ ):wtFiber DNA, and transfected into cells expressing  $\alpha_4$  integrins. The  $\alpha_4$  integrins can serve as both the attachment and internalization receptors for the Ad5 rcPB5 ( $\alpha_4$ ):-Fiber virus.

Example 7

This example illustrates the creation of recombinant adenovirus particles lacking fiber protein and containing chimeric penton base with an epitope recognized by a monoclonal antibody (antibody-specific sequence).

Viral DNA is isolated from an Ad5 virus lacking fiber, as in Example 6, and digested with the endonuclease Xmn I as in Example 5. The pAT vector containing the chimeric penton base gene containing the sequence encoding the antibody-specific epitope is prepared as in Example 5. The digested viral and pAT DNA is transfected into 293 cells to produce virus by homologous recombination. The recombinant virus is passaged and amplified by incubating cell lysates with a bispecific antibody to  $\alpha_v$  integrins (expressed and internalized in 293 cells) and the antibody-specific epitope on the chimeric penton base, thereby allowing the recombinant virus to attach and infect the 293 cells. The virus progeny from infected cells lack the bispecific antibody so that following their purification from infected cells they can be targeted to HIV-infected cells by combining them with a bispecific antibody recognizing the antibody-specific epitope in the chimeric penton base and the HIV gp120.

Example 8

This example illustrates the creation of recombinant adenovirus particles containing chimeric fiber protein specific for sialyl Lewis X antigen and chimeric penton base specific for  $\alpha_4$  integrins [Ad5 rcPB5 ( $\alpha_4$ ):rdFiber (sLX)].

The protein P-selectin binds to sialyl Lewis X antigen present on lymphocytes. The binding domain from P-selectin is present on the rcFiber (sLX) protein to mediate virus binding. The left arm (0-59 m.u.) of the Ad5 rcPB5 ( $\alpha_4$ ):wtFiber virus can be prepared by Bam HI digestion and then purified.

The rcFiber (sLX) gene can be cloned into the plasmid containing the 59-100 m.u. fragment of the Ad5 genome. The rcFiber (sLX) gene then can replace the wtFiber gene. The 59-100 m.u. Ad5 fragment containing rcFiber (sLX) then can be ligated to the 0-59 m.u. Ad5 fragment containing rcPB5 ( $\alpha_4$ ). The ligated fragment then can be transfected into cells expressing the receptors for attachment (sialyl Lewis X) and internalization ( $\alpha_4$  integrins) for the chimeric virus Ad5 rcPB5 ( $\alpha_4$ ):rcFiber (sLX).

#### Example 9

This example illustrates the creation of recombinant adenovirus particles containing chimeric hexon protein specific for sialyl Lewis X antigen, chimeric penton base specific for  $\alpha_4$  integrins, and lacking fiber protein [Ad5 rcPB5 ( $\alpha_4$ ):-Fiber:rcHexon (sLX)].

The protein P-selectin binds to sialyl Lewis X antigen present on lymphocytes. The binding domain from P-selection is present within an exposed loop on wtHexon, and the resultant rcHexon (sLX) protein can mediate virus binding. Genes encoding rcPB5 ( $\alpha_4$ ) and rcHexon (sLX) can be cloned into the pAT vector that contains the penton base gene and the region encoding the exposed loop of hexon protein. A ligation of three fragments can be performed to generate the recombinant virus. Ad5 rcPB5 ( $\alpha_4$ ):-Fiber virus may be digested with Eco RI and Bam HI. The left end of the genome up to the Eco RI site and the right end of the genome down to the Bam HI site can be purified and ligated with the Eco RI/Bam HI fragment from the pAT vector containing rcPB5 ( $\alpha_4$ ) and rcHexon (sLX). The ligated fragment then can be transfected into cells expressing the receptors for attachment (sialyl Lewis X) and internalization ( $\alpha_4$  integrins) for the chimeric virus Ad5 rcPB5 ( $\alpha_4$ ):rcFiber (sLX).

Example 10

This example describes the expression of wild-type Ad5 and mutant rcPB5 ( $\Delta$ RGD) penton base protein in baculovirus.

5        Using PCR, the wild-type Ad5 penton base sequence was amplified with an Eco RI site inserted at the 5' end of the gene. This gene was then cloned into the pAT vector and then subcloned into the pAcSG2 baculoviral transfer vector, using methods known in the art.

10       Recombinant baculovirus encoding the Ad5 penton base gene (AcNPV wtPB5) produced levels of penton base protein in insect cells that constituted approximately 50% of the total cellular protein. The purified wtPB5 protein migrated consistently with respect to its known molecular  
15       weight on SDS-PAGE and can mediate cell adhesion like Ad2 penton base (Wickham et al. (1993), supra).

      The core baculoviral transfer vector, pRcPB5 ( $\Delta$ RDG), for expression of rcPB5 protein in the baculoviral expression system, has been used to make recombinant  
20       baculovirus, which expresses rcPB5 protein. This rcPB5 protein, rcPB5 ( $\Delta$ RGD), contains an 8 amino acid deletion in the RGD region as shown in Figure 2, which is a partial restriction map of the vector pRcPB5 ( $\Delta$ RGD). This protein migrates consistently with respect to its  
25       known molecular weight on SDS-PAGE and, in contrast to the wild-type protein (wtPB5), does not mediate cell adhesion, which is consistent with its lack of the RGD cell adhesion motif. Chimeric recombinant penton base molecules rcPB5 ( $\alpha_v\beta_3$ ) and rcPB5 ( $\alpha_4$ ), each containing  
30       inserts specific for  $\alpha_v\beta_3$  and  $\alpha_4$  integrins, respectively, also have been produced via the core baculoviral transfer vector, pRcPB5 ( $\Delta$ RGD). The rcPB5 ( $\alpha_v\beta_3$ ) protein mediates epithelial cell ( $\alpha_v+$ ,  $\alpha_4-$ ), but not lymphocyte ( $\alpha_v-$ ,  $\alpha_4+$ ), adhesion; in contrast, RcPB5 ( $\alpha_4$ ) supports lymphocyte,  
35       but not epithelial cell, adhesion.

Example 11

This example illustrates the targeting of adenovirus to lymphocytes.

The transfer vectors pAT ( $\alpha_v\beta_3$ ) and pAT ( $\alpha_4$ ) were  
5 created by cloning the Eco RI/Bgl II fragments from their  
respective pRcPB5 vectors into the pAT ( $\Delta$ RGD) vector.  
These pAT vectors were then linearized by Bam HI  
digestion and transfected with Xmn I-digested viral DNA  
10 from an Ad5 variant, which lacks the E1 and E3 regions  
and contains a  $\beta$ -galactosidase reporter gene under  
control of a CMV promoter, to obtain recombinant Ad5  
virus, namely Ad5 rcPB ( $\Delta$ RGD), Ad5 rcPB ( $\alpha_v\beta_3$ ), and Ad5  
rcPB ( $\alpha_4$ ), through homologous recombination. The Xmn I  
15 endonuclease cuts the wild-type Ad5 at positions 14561  
and 15710 within the genome, while the Bam HI/Pme I  
fragment contained in the pAT vector spans the Ad5 region  
of 13258 to 21562. Thus, the regions of homologous  
overlap between the left and right viral sequences with  
the Bam HI/Pme I fragment are 1303 bp and 5851 bp,  
20 respectively. The presence of the chimeric inserts in  
the Ad5 rcPB ( $\alpha_v\beta_3$ ) and Ad5 rcPB ( $\alpha_4$ ) viruses are verified  
through PCR.

The recombinant adenovirus Ad5 rcPB ( $\alpha_4$ ) is analyzed  
for its targeting potential in relation to wild-type Ad5  
25 and recombinant Ad5 rcPB ( $\Delta$ RGD) by measuring levels of  
the reporter gene expression in cells exposed to each of  
the viruses. Delivery of  $\beta$ -galactosidase to the B-  
lymphocyte cell line, Ramos, is significantly higher  
using the Ad5 rcPB ( $\alpha_4$ ) virus than the Ad5 rcPB ( $\Delta$ RGD)  
30 and wild-type Ad5 viruses. Conversely, delivery of  $\beta$ -  
galactosidase to an epithelial-derived cell line is  
significantly higher than the wild-type Ad5 virus in  
comparison to the Ad5 rcPB ( $\alpha_4$ ) and Ad5 rcPB ( $\Delta$ RGD)  
viruses. These results demonstrate that changes in  
35 penton base protein that redirect the protein to interact  
with a new receptor can be utilized to target the virus

to new cells and tissues while specifically avoiding delivery to other cells and tissues.

5 All publications cited herein are hereby incorporated by reference to the same extent as if each publication were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

10 While this invention has been described with emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that the preferred embodiments may be varied. It is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes  
15 all modifications encompassed within the spirit and scope of the appended claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Wickham, Thomas J.  
Kovesdi, Imre  
Brough, Douglas E.  
McVey, Duncan L.  
Bruder, Joseph T.
- (ii) TITLE OF INVENTION: CHIMERIC PENTON BASE MOLECULES  
AND METHODS OF USING SAME
- (iii) NUMBER OF SEQUENCES: 24
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Leydig, Voit & Mayer
  - (B) STREET: Two Prudential Plaza, Suite 4900
  - (C) CITY: Chicago
  - (D) STATE: Illinois
  - (E) COUNTRY: USA
  - (F) ZIP: 60601
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Kilyk, John Jr.
  - (B) REGISTRATION NUMBER: 30763
  - (C) REFERENCE/DOCKET NUMBER: 61306
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (312) 616-5600
  - (B) TELEFAX: (312) 616-5700

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Arg Gly Asp  
1

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid



31

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Lys Gln Ala Gly Asp  
1 5

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Glu Ile Leu Asp Val  
1 5

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asn Pro Xaa Try  
1

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 65 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 51..65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTCACCAAGG CCATGGCACC GAGCGTTGGT TTTCTTGAAT TCCCCTTAGT ATG CGG  
Met Arg

56

32

CGC GCG GCG  
Arg Ala Ala  
5

1

65

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Arg Arg Ala Ala  
1 5

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 65 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

- (ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 51..65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTCACCAAGG CCATGGCACC GAGCGTTGGT TTTCTTGTAT TCCCCTTAGT ATG CGG 56  
Met Arg  
1

CGC GCG GCG  
Arg Ala Ala  
5

65

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Arg Arg Ala Ala  
1 5

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double

33

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAC ATG AAC GAT ACT AGT GCC ACA CGG GCT  
 Asp Met Asn Asp Thr Ser Ala Thr Arg Ala  
 1 5 10

30

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp Met Asn Asp Thr Ser Ala Thr Arg Ala  
 1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..48

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GAC ATG AAC GAT CAT GCC ATT CGC GGC GAC ACC TTT GCC ACA CGG GCT  
 Asp Met Asn Asp His Ala Ile Arg Gly Asp Thr Phe Ala Thr Arg Ala  
 1 5 10 15

48

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Asp Met Asn Asp His Ala Ile Arg Gly Asp Thr Phe Ala Thr Arg Ala  
 1 5 10 15

34

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 52 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: DNA (synthetic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAAAC TCACC AAGGCCATGG CACCGAGCGT TGGTTTTCTT GAATTCCCCT TA

52

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: DNA (synthetic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CTGGCGGGCG CGCCAAAATC TGGTT

25

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: DNA (synthetic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

AAAAC TAGTG CCACACGGGC TGAGGA

26

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: DNA (synthetic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AAAAC TAGTA TCGTTCATGT CCTCCA

26

## (2) INFORMATION FOR SEQ ID NO:17:

35

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..68

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AA	ACT	AGT	GGA	GGA	TGC	TCT	TTT	GGC	CGC	GGC	GAC	ATT	CGC	AAC	TGC	47
	Thr	Ser	Gly	Gly	Cys	Ser	Phe	Gly	Arg	Gly	Asp	Ile	Arg	Asn	Cys	
	1			5					10					15		
GGC	GGC	CTG	CAG	TCT	AGA	AAA										68
Gly	Gly	Leu	Gln	Ser	Arg	Lys										
			20													

(2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Thr	Ser	Gly	Gly	Cys	Ser	Phe	Gly	Arg	Gly	Asp	Ile	Arg	Asn	Cys	Gly
1				5					10					15	
Gly	Leu	Gln	Ser	Arg	Lys										
			20												

(2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AA	ACTAGTGG	AGGATGCTCT	TTTGGCCGCG	GCGACATTCG	C	41
----	----------	------------	------------	------------	---	----

(2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (synthetic)

36

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TTTTCTAGAC TGCAGGCCGC CGCAGTTGCG AATGTCGCCG CG

42

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 110 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..110

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AA	ACT	AGT	GGA	GGA	GAC	GAG	CTC	CCA	CAG	CTC	GTG	ACT	CTC	CCA	CAC		47
	Thr	Ser	Gly	Gly	Asp	Glu	Leu	Pro	Gln	Leu	Val	Thr	Leu	Pro	His		
	1				5					10					15		
CCA	AAC	CTC	CAC	GGT	CCA	GAG	ATT	CTC	GAC	GTG	CCA	TCT	ACT	GGC	GGC		95
Pro	Asn	Leu	His	Gly	Pro	Glu	Ile	Leu	Asp	Val	Pro	Ser	Thr	Gly	Gly		
				20					25					30			110
CTG	CAG	TCT	AGA	AAA													
Leu	Gln	Ser	Arg	Lys													
				35													

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Thr	Ser	Gly	Gly	Asp	Glu	Leu	Pro	Gln	Leu	Val	Thr	Leu	Pro	His	Pro		
1				5					10					15			
Asn	Leu	His	Gly	Pro	Glu	Ile	Leu	Asp	Val	Pro	Ser	Thr	Gly	Gly	Leu		
			20					25					30				
Gln	Ser	Arg	Lys														
			35														

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 65 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

37

AAACTAGTGG AGGAGACGAG CTCCCACAGC TCGTGACTCT CCCACACCCA AACCTCCACG 60  
GTCCA 65

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TTTTCTAGAC TGCAGGCCGC CAGTAGATCG CACGTCGAGA ATCTCTGGAC CGTGGAGGTT 60

WHAT IS CLAIMED IS:

1. A recombinant adenovirus comprising (a) a  
chimeric penton base protein, wherein said chimeric  
5 penton base protein comprises a nonpenton base amino acid  
sequence, which is specific for binding to a receptor, a  
receptor-specific antibody domain or epitope, in addition  
to or in place of a wild-type penton base amino acid  
sequence, which is specific for binding to a receptor,  
10 and (b) a therapeutic gene that is capable of being  
expressed in a cell to which the recombinant adenovirus  
has attached or by which the recombinant adenovirus has  
been internalized.
- 15 2. The recombinant adenovirus of claim 1, wherein  
said wild-type penton base amino acid sequence is an RGD  
amino acid sequence.
- 20 3. The recombinant adenovirus of claim 2, wherein  
said recombinant adenovirus is fiberless.
- 25 4. The recombinant adenovirus of claim 2, which  
further comprises, in addition to the chimeric penton  
base protein, a chimeric coat protein which includes an  
amino acid sequence that is specific for binding to a  
25 receptor, a receptor-specific antibody domain or epitope.
- 30 5. The recombinant adenovirus of claim 4, wherein  
said amino acid sequence in said chimeric coat protein,  
which is specific for binding to a receptor, a receptor-  
specific antibody domain or an epitope, is specific for  
binding to the same receptor, antibody domain or epitope  
as the nonpenton base amino acid sequence in said  
chimeric penton base protein.



6. The recombinant adenovirus of claim 4, wherein said chimeric coat protein is selected from the group consisting of a chimeric fiber and a chimeric hexon.

5           7. The recombinant adenovirus of claim 6, wherein said amino acid sequence in said chimeric coat protein, which is specific for binding to a receptor, a receptor-specific antibody domain or epitope, is specific for binding to the same receptor, antibody domain or epitope  
10 as the nonpenton base amino acid sequence in said chimeric penton base protein.

          8. A recombinant baculovirus comprising a chimeric adenoviral penton base gene sequence encoding a chimeric  
15 penton base protein, which chimeric adenoviral penton base gene sequence comprises (a) a nonpenton base gene sequence encoding an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope, and (b) a wild-type penton base gene  
20 sequence that encodes an amino acid sequence that is specific for binding to a receptor.

          9. The recombinant baculovirus of claim 8, wherein said wild-type penton base gene sequence encodes an RGD  
25 amino acid sequence.

          10. The recombinant baculovirus of claim 9, wherein the gene sequence encoding the RGD amino acid sequence has been mutated.  
30

          11. The recombinant baculovirus of claim 10, wherein the gene sequence encoding the RGD amino acid sequence has been mutated by insertion of the nonpenton base gene sequence into the gene sequence encoding the  
35 RGD amino acid sequence.

12. The recombinant baculovirus of claim 9, wherein the gene sequence encoding the RGD amino acid sequence has been moved within the penton base gene sequence such that in the chimeric penton base protein the RGD amino acid sequence is conformationally inaccessible for binding to a receptor.

13. The recombinant baculovirus of claim 12, wherein the gene sequence encoding the RGD amino acid sequence has been moved within the penton base gene sequence by insertion of the nonpenton base gene sequence near the gene sequence encoding the RGD amino acid.

14. A recombinant baculovirus comprising a chimeric adenoviral penton base gene sequence, wherein said chimeric adenoviral penton base gene sequence includes a nonpenton base gene sequence, which encodes an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in place of a wild-type penton base gene sequence that encodes an amino acid sequence that is specific for binding to a receptor.

15. The recombinant baculovirus of claim 14, wherein said wild-type penton base gene sequence encodes an RGD amino acid sequence.

16. A chimeric adenoviral penton base protein comprising a nonpenton base amino acid sequence, which is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in addition to or in place of a wild-type penton base amino acid sequence, which is specific for binding to a receptor.

17. The chimeric adenoviral penton base protein of claim 16, wherein said wild-type penton base amino acid sequence is an RGD amino acid sequence.

18. A viral transfer vector comprising a chimeric adenoviral penton base gene sequence encoding a chimeric penton base protein, which chimeric adenoviral penton base gene sequence comprises a nonpenton base gene sequence encoding an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in addition to a wild-type penton base gene sequence that encodes an amino acid sequence that is specific for binding to a receptor.

19. The viral transfer vector of claim 18, wherein said viral transfer vector is an adenoviral transfer vector.

20. The viral transfer vector of claim 19, wherein said wild-type penton base gene sequence encodes an RGD amino acid sequence.

21. The viral transfer vector of claim 20, wherein the gene sequence encoding the RGD amino acid sequence has been mutated.

22. The viral transfer vector of claim 21, wherein the gene sequence encoding the RGD amino acid sequence has been mutated by insertion of the nonpenton base gene sequence into the gene sequence encoding the RGD amino acid sequence.

23. The viral transfer vector of claim 20, wherein the gene sequence encoding the RGD amino acid sequence has been moved within the penton base gene sequence such that in the chimeric penton base protein the RGD amino acid sequence is conformationally inaccessible for binding to a receptor.

24. The viral transfer vector of claim 23, wherein the gene sequence encoding the RGD amino acid sequence

has been moved by insertion of the nonpenton base gene sequence near the gene sequence encoding the RGD amino acid sequence.

5           25. A viral transfer vector comprising a chimeric adenoviral penton base gene sequence encoding a chimeric penton base protein, which chimeric adenoviral penton base gene sequence comprises a nonpenton base gene sequence encoding an amino acid sequence that is specific  
10           for binding to a receptor, a receptor-specific antibody domain or epitope, in place of a wild-type penton base gene sequence that encodes an amino acid sequence that is specific for binding to a receptor.

15           26. The viral transfer vector of claim 25, wherein said viral transfer vector is an adenoviral transfer vector.

20           27. The viral transfer vector of claim 26, wherein said wild-type penton base gene sequence encodes an RGD amino acid sequence.

25           28. A prokaryotic or eukaryotic expression vector comprising a chimeric adenoviral penton base gene sequence encoding a chimeric penton base protein, which  
30           chimeric adenoviral penton base gene sequence comprises a nonpenton base gene sequence encoding an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in place of  
a wild-type penton base gene sequence that encodes an amino acid sequence that is specific for binding to a receptor.

35           29. The prokaryotic or eukaryotic expression vector of claim 28, wherein said wild-type penton base gene sequence encodes an RGD amino acid sequence.

30. A prokaryotic or eukaryotic expression vector comprising a chimeric adenoviral penton base gene sequence encoding a chimeric penton base protein, which chimeric adenoviral penton base gene sequence comprises a nonpenton base gene sequence encoding an amino acid sequence that is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in addition to a wild-type penton base gene sequence that encodes an amino acid sequence that is specific for binding to a receptor.

31. The prokaryotic or eukaryotic expression vector of claim 30, wherein said wild-type penton base gene sequence encodes an RGD amino acid sequence.

32. The prokaryotic or eukaryotic expression vector of claim 31, wherein the gene sequence encoding the RGD amino acid sequence has been mutated.

33. The prokaryotic or eukaryotic expression vector of claim 32, wherein the gene sequence encoding the RGD amino acid sequence has been mutated by insertion of the nonpenton base gene sequence into the gene sequence encoding the RGD amino acid sequence.

34. The prokaryotic or eukaryotic expression vector of claim 31, wherein the gene sequence encoding the RGD amino acid sequence has been moved within the penton base gene sequence such that in the chimeric penton base protein the RGD amino acid sequence is conformationally inaccessible for binding to a receptor.

35. The prokaryotic or eukaryotic expression vector of claim 34, wherein the gene sequence encoding the RGD amino acid sequence has been moved by insertion of the nonpenton base gene sequence near the gene sequence encoding the RGD amino acid sequence.

36. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 1.

5

37. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 2.

10

38. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 3.

15

39. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 4.

20

40. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 5.

25

41. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 6.


30

42. A method of gene therapy comprising administering to a patient in need of gene therapy a therapeutically effective amount of a recombinant adenovirus of claim 7.



FIG. 2

2/2



**SpeI**

GACATGAACGATACTAGTGCCACACGGGCT **New Sequence**  
 ▶AspMetAsnAspThrSerAlaThrArgAla

4584 GACATGAACGATCATGCCATTTCGGGGCGACACCTTTGCCACACGGGCT **Wild-type Sequence**  
 1▶ArgGlyAsp  
 1▶AspMetAsnAspHisAlaIleArgGlyAspThrPheAlaThrArgAla






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 15/87, 7/01, 15/12, C12N 15/34, 15/62, A61K 48/00</b>		<b>A3</b>	(11) International Publication Number: <b>WO 96/07734</b>
			(43) International Publication Date: 14 March 1996 (14.03.96)
(21) International Application Number: PCT/US95/09904		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 7 August 1995 (07.08.95)		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 303,162 8 September 1994 (08.09.94) US		(88) Date of publication of the international search report: 9 May 1996 (09.05.96)	
(71) Applicant: GENVEC, INC. [US/US]; 12111 Parklawn Drive, Rockville, MD 20852 (US).			
(72) Inventors: WICKHAM, Thomas, J.; 8608 Delcris Drive, Gaithersburg, MD 20879 (US). KOVESDI, Imre; 12505 Village Square Terrace #202, Rockville, MD 20852 (US). BROUGH, Douglas, E.; 3900 Shallowbrook Lane, Olney, MD 20832 (US). McVEY, Duncan, L.; 7727 Ironforge Court, Derwood, MD 20855 (US). BRUDER, Joseph, T.; 6644 Beach Drive, New Market, MD 21774 (US).			
(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).			

(54) Title: RECOMBINANT ADENOVIRUS COMPRISING A CHIMERIC PENTON BASE PROTEIN



## (57) Abstract

A recombinant adenovirus comprising a chimeric penton base protein, which includes a nonpenton base sequence, and a therapeutic gene, a method of gene therapy involving the use of such adenovirus, and adenoviral transfer vectors for the generation of such recombinant adenovirus are provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/US 95/09904

## A. CLASSIFICATION OF SUBJECT MATTER

 IPC 6 C12N15/86 C12N15/87 C12N7/01 C12N15/12 C12N15/34  
 C12N15/62 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 17832 (SCRIPPS RESEARCH INST ;NEMEROW GLEN R (US); WICKHAM THOMAS J (US)) 18 August 1994 see the whole document ---	1-42
A	TRENDS IN CELL BIOLOGY 4 (2). 1994. 52-55. ISSN: 0962-8924, February 1994 NEMEROW G R ET AL 'Adenovirus entry into host cells: A role for alpha-v integrins.' see the whole document --- -/--	1-42

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

11 March 1996

Date of mailing of the international search report

15.03.96

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+ 31-70) 340-3016

Authorized officer

Hornig, H

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/09904

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CELL, vol. 73, no. 2, 23 April 1993 CELL PRESS,CAMBRIDGE,MA,US;; pages 309-319, T.J. WICKHAM ET AL. 'Integrins alphavbeta3 and alphavbeta5 promote Adenovirus internalization but not virus attachment' cited in the application see the whole document ---</p>	1-42
A	<p>J. BIOL. CHEM. (1991), 266(6), 3961-7 CODEN: JBCHA3;ISSN: 0021-9258, 25 February 1991 ALBIGES-RIZO, CORINNE ET AL 'Human adenovirus serotype 3 fiber protein. Comparison of native and recombinant proteins' see the whole document ---</p>	1-42
A	<p>VIROLOGY, vol. 185, no. 1, November 1991 ACADEMIC PRESS, INC.,NEW YORK, US, pages 365-376, A. NOVELLI AND P.A. BOULANGER 'Deletion analysis of functional domains in Baculovirus-expressed Adenovirus type 2 fiber' see the whole document ---</p>	1-42
A	<p>VIROLOGY, vol. 185, no. 2, December 1991 ACADEMIC PRESS, INC.,NEW YORK, US, pages 758-767, J.S. HONG AND J.A. ENGLER 'The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal ' see the whole document ---</p>	1-42
T	<p>GENE THER. (1995), 2(10), 750-6 CODEN: GETHEC;ISSN: 0969-7128, December 1995 WICKHAM, T. J. ET AL 'Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs' see the whole document -----</p>	1-42

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 09904

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 36-42 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Information on patent family members

PCT, JS 95/09904

Form PCT/ISA/210 (patent family annex) (July 1992)